Industry
This funding aims to propel the development of bacterial products and therapies that are not only unique but immune to viruses, enhancing their therapeutic potential.
Microbiomepost conducted an exclusive interview with Jiri Snaidr, Founder and CEO at Vermicon AG, about the possibility to combine Fluorescence In Situ Hybridization (FISH) and Digital PCR (dPCR) for advanced…
An innovative tool for higher yields and greater efficiency
Microbiomepost conducted an exclusive interview with Eric Daliri, from Vilnius University, about the possibility of prevent diabetes modulating gut microbiome.
Microbiomepost conducted an exclusive interview with Nina Vinot, Bioprox Healthcare, about the new frontiers of the microbiome revolution: the role of soil microbiome in the agriculture space.
Alessio Fasano, Chair of the Congress, shares an overview of the event and the future challenges.
Industry
Sponsored by
The Research and Development laboratories of Biofarma Group have developed a formulation that can represent a valid aid in case of vaginal dysbiosis and associated disorders.
Key areas of interest include circadian rhythms, neurological conditions, metabolic disorders, and oncology.
During IPC 2024, George Paraskevakos shared recent updates on market developments and an overview of the Biotic-related survey.
VOWST is the first and only orally administered microbiota-based therapeutic approved by the U.S. FDA for the prevention of recurrent Clostridioides difficile infection in adults.
